Aditxt, Inc. (NASDAQ:ADTX) Short Interest Up 102.9% in March

Aditxt, Inc. (NASDAQ:ADTX) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 35,100 shares, a growth of 102.9% from the February 29th total of 17,300 shares. Approximately 1.8% of the company’s stock are short sold. Based on an average daily volume of 570,800 shares, the days-to-cover ratio is currently 0.1 days.

Aditxt Price Performance

ADTX opened at $3.40 on Friday. The business’s 50-day moving average price is $3.62 and its two-hundred day moving average price is $6.32. Aditxt has a 1 year low of $2.95 and a 1 year high of $76.40.

Institutional Trading of Aditxt

Several hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in shares of Aditxt in the second quarter valued at about $71,000. Bank of New York Mellon Corp acquired a new stake in shares of Aditxt in the third quarter valued at about $119,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Aditxt in the third quarter valued at about $423,000. Finally, Armistice Capital LLC acquired a new stake in shares of Aditxt in the third quarter valued at about $350,000. Institutional investors and hedge funds own 15.54% of the company’s stock.

About Aditxt

Aditxt, Inc, a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.